NEW HAVEN — Four bioscience projects were awarded a piece of a $2 million pie to speed up their paths to commercialization.

Connecticut Innovations Inc. (CII) doled out funds through the Connecticut Bioscience Innovation Fund (CBIF) to both a pair of Yale-based projects and a pair centered at UConn.

Demetrios Braddock, associate professor of pathology at the Yale School of Medicine and medical director of Principio Diagnostics, was awarded $500,000 to fund a treatment for a fatal orphan disease resulting in heart failure and cardiac arrest. CaroGen Corp., a Hepatitis B vaccine developer that originated at the Yale School of Medicine, also received $500,000 in funding.

Quing Zhu, associate professor of electrical & computer engineering at UConn, received $500,000 for development of a hand-held infrared imager for use with ultrasound machines. Dura Biotech of Storrs received $400,368 to fund development and testing of a lower-diameter valve for use in aortic valve replacement surgeries.

The CBIF was established in 2013 to support promising bioscience projects statewide, with a focus on startups, early-stage businesses, non-profits and accredited colleges and universities. The $200 million fund is managed by Connecticut Innovations, which will distribute grants and loans over ten years.

CII also recently awarded Branford life sciences tool company IsoPlexis a $300,000 grant to develop a beta version and conduct testing of its cancer therapy device that provides cellular data to drug makers.